{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,5]],"date-time":"2026-03-05T03:04:13Z","timestamp":1772679853727,"version":"3.50.1"},"reference-count":8,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2021,6,1]],"date-time":"2021-06-01T00:00:00Z","timestamp":1622505600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,6,1]],"date-time":"2021-06-01T00:00:00Z","timestamp":1622505600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","ejcancer.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Cancer"],"published-print":{"date-parts":[[2021,6]]},"DOI":"10.1016\/j.ejca.2021.03.046","type":"journal-article","created":{"date-parts":[[2021,5,3]],"date-time":"2021-05-03T16:38:33Z","timestamp":1620059913000},"page":"211-213","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":7,"special_numbering":"C","title":["Lenvatinib and osteonecrosis of the jaw: A\u00a0pharmacovigilance study"],"prefix":"10.1016","volume":"150","author":[{"given":"Wenchao","family":"Lu","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0794-5918","authenticated-orcid":false,"given":"Qixiang","family":"Guo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zhuo","family":"Ma","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lihong","family":"Liu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zhixia","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.ejca.2021.03.046_bib1","doi-asserted-by":"crossref","first-page":"e302","DOI":"10.1634\/theoncologist.2019-0407","article-title":"Lenvatinib in management of solid tumors","volume":"25","author":"Hao","year":"2020","journal-title":"Oncol"},{"key":"10.1016\/j.ejca.2021.03.046_bib2","doi-asserted-by":"crossref","first-page":"2270","DOI":"10.1200\/JCO.19.01186","article-title":"Medication-related osteonecrosis of the jaw: MASCC\/ISOO\/ASCO clinical practice guideline","volume":"37","author":"Yarom","year":"2019","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ejca.2021.03.046_bib3","series-title":"Questions and answers on FDA's Adverse Event Reporting System (FAERS)","year":"2019"},{"key":"10.1016\/j.ejca.2021.03.046_bib4","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1038\/sj.clpt.6100258","article-title":"Novel statistical tools for monitoring the safety of marketed drugs","volume":"82","author":"Almenoff","year":"2007","journal-title":"Clin Pharmacol Ther"},{"key":"10.1016\/j.ejca.2021.03.046_bib5","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1111\/j.1365-2125.2007.02900.x","article-title":"Detecting signals of drug\u2013drug interactions in a spontaneous reports database","volume":"64","author":"Thakrar","year":"2007","journal-title":"Br J Clin Pharmacol"},{"key":"10.1016\/j.ejca.2021.03.046_bib6","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1056\/NEJMoa1406470","article-title":"Lenvatinib versus placebo in radioiodine-refractory thyroid cancer","volume":"372","author":"Schlumberger","year":"2015","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ejca.2021.03.046_bib7","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1016\/j.ctrv.2015.04.007","article-title":"Drug induced osteonecrosis of the jaw","volume":"41","author":"Hamadeh","year":"2015","journal-title":"Canc Treat Rev"},{"key":"10.1016\/j.ejca.2021.03.046_bib8","doi-asserted-by":"crossref","first-page":"l1733","DOI":"10.1136\/bmj.l1733","article-title":"Preventing medication-related osteonecrosis of the jaw","author":"Zebic","year":"2019","journal-title":"BMJ"}],"container-title":["European Journal of Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0959804921002136?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0959804921002136?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,17]],"date-time":"2025-10-17T20:32:13Z","timestamp":1760733133000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0959804921002136"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,6]]},"references-count":8,"alternative-id":["S0959804921002136"],"URL":"https:\/\/doi.org\/10.1016\/j.ejca.2021.03.046","relation":{},"ISSN":["0959-8049"],"issn-type":[{"value":"0959-8049","type":"print"}],"subject":[],"published":{"date-parts":[[2021,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Lenvatinib and osteonecrosis of the jaw: A\u00a0pharmacovigilance study","name":"articletitle","label":"Article Title"},{"value":"European Journal of Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejca.2021.03.046","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"simple-article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}